نتائج البحث - "O. A. Prikolota"

المصدر: The Russian Archives of Internal Medicine; Том 13, № 6 (2023); 436-448 ; Архивъ внутренней медицины; Том 13, № 6 (2023); 436-448 ; 2411-6564 ; 2226-6704

مصطلحات موضوعية: резистентная артериальная гипертония, arterial hypertension, isolated systolic arterial hypertension, resistant arterial hypertension, артериальная гипертония, изолированная систолическая артериальная гипертония

وصف الملف: application/pdf

العلاقة: https://www.medarhive.ru/jour/article/view/1692/1273Test; https://www.medarhive.ru/jour/article/view/1692/1281Test; Petrie J.R., Guzik T.J., Touyz R.M. Diabetes, Hypertension, and Cardiovascular Disease: Clinical Insights and Vascular Mechanisms. Can J Cardiol. 2018; 34(5): 575-584. doi:10.1016/j.cjca.2017.12.005.; Pavlou D.I., Paschou S.A., Anagnostis P. et al. Hypertension in patients with type 2 diabetes mellitus: Targets and management. Maturitas. 2018; 112: 71-77. doi:10.1016/j.maturitas.2018.03.013; Кобалава Ж.Д., Конради А.О., Недогода С.В. и др. 2022 Российское кардиологическое общество. Артериальная гипертензия у взрослых. Клинические рекомендации (проект). [Электронный ресурс] doi: https://scardio.ru/content/Guidelines/project/KR_AG.pdfTest; Boned Ombuena P., Rodilla Sala E., Costa Muñoz J.A. et al. Hipertensión arterial y prediabetes [Arterial hypertension and prediabetes]. Med Clin (Barc). 2016; 147(9): 387-392. Spanish. doi:10.1016/j.medcli.2016.06.032; Vallée A., Safar M.E., Blacher J. Hypertension artérielle permanente essentielle: définitions et revue hémodynamique, clinique et thérapeutique [Essential hypertension: Definitions, hemodynamic, clinical and therapeutic review]. Presse Med. 2019; 48(1 Pt 1): 19-28. French. doi:10.1016/j.lpm.2018.11.017. Epub 2019 Jan 18. PMID: 30665781.; Cordero A., Lekuona I., Galve E. et al. Sección de Hipertensión Arterial, Grupo de Trabajo Corazón y Diabetes, Grupo de Trabajo Cardio-Renal, Sociedad Española de Cardiología, España. Novedades en hipertensión arterial y diabetes mellitus [Advances in arterial hypertension and diabetes mellitus]. Rev Esp Cardiol (Engl Ed). 2012; 65 Suppl 1: 12-23. Spanish. doi:10.1016/j.recesp.2011.10.030. PMID: 22269836.; Cockcroft J.R., Webb D.J., Wilkinson I.B. Arterial stiffness, hypertension and diabetes mellitus. J Hum Hypertens. 2000; 14(6): 377-80. doi:10.1038/sj.jhh.1001023. PMID: 10878698.; Hadjkacem F., Triki F., Frikha H. et al. L’hypertension artérielle masquée chez les diabétiques de type 2: Prévalence, facteurs associés et retentissement cardiovasculaire [Masked arterial hypertension in patients with type2 diabetes mellitus: Prevalence, associated factors and cardiovascular impact]. Ann Cardiol Angeiol (Paris). 2022; 71(3): 136-140. French. doi:10.1016/j.ancard.2021.10.018.; Rolim L.P., Samelli A.G., Moreira R.R. et al. Effects of diabetes mellitus and systemic arterial hypertension on elderly patients’ hearing. Braz J Otorhinolaryngol. 2018; 84(6): 754-763. doi:10.1016/j.bjorl.2017.08.014.; Abrignani M.G. Physical exercise and risk of arterial hypertension and diabetes mellitus. Let’s move, it is never too late. Eur J Prev Cardiol. 2018; 25(10): 1063-1064. doi:10.1177/2047487318781116.; Дедов И.И., Шестакова М.В., Майоров А.Ю. и др. Клинические рекомендации 2022 Сахарный диабет 2 типа у взрослых. 2022: 1-251. https://diseases.medelement.com/diseaseTest/сахарныйдиабет-2-типа-у-взрослых-кр-рф-2022/17220; Draznin B., Aroda V.R., Bakris G. et al. 10. Cardiovascular Disease and Risk Management: Standards of Medical Care in Diabetes-2022 American Diabetes Association Professional Practice Committee. 2022; 45(Suppl 1): 144-174. doi:10.2337/dc22-S010.; Smulyan H., Lieber A., Safar M.E. Hypertension, Diabetes Type II, and Their Association: Role of Arterial Stiffness. Am J Hypertens. 2016; 29(1): 5-13. doi:10.1093/ajh/hpv107.; Tirapani L.D.S., Fernandes N.M.D.S. A narrative review of the impacts of income, education, and ethnicity on arterial hypertension, diabetes mellitus, and chronic kidney disease in the world. Saudi J Kidney Dis Transpl. 2019; 30(5): 1084-1096. doi:10.4103/1319-2442.270264.; de Lira C.A.B., Viana R.B., Luz N.F., et al. Analysis of type 2 diabetes mellitus and arterial hypertension content in exercise physiology textbooks. Adv Physiol Educ. 2019; 43(3): 253-258. doi:10.1152/advan.00043.2019.; Scheen A.J. Renin-angiotensin system inhibition prevents type 2 diabetes mellitus. Part 2. Overview of physiological and biochemical mechanisms. Diabetes Metab. 2004; 30: 498–505. https://www.sciencedirect.com/science/article/abs/pii/S1262363607701477Test; Филимонова А.С., Расова С.А., Сопенко И.В. и др. Артериальная гипертензия и связанные с ней факторы у пациентов с сахарным диабетом 2 типа. Актуальные научные исследования в современном мире. 2021; № 12-1(80): 143-148.; Rishko O.A., Derbak M.A., Ihnatko Y.Y. et al. The clinical experience of the effective use of dapagliflozin in comorbid cardiac patients with concomitant type 2 diabetes mellitus and arterial hypertension on the background of overweight in outpatient setting. Wiad Lek. 2022; 75(10): 2397-2401. doi:10.36740/WLek202210114.; Berra C., Manfrini R., Regazzoli D. et al. Blood pressure control in type 2 diabetes mellitus with arterial hypertension. The important ancillary role of SGLT2-inhibitors and GLP1-receptor agonists. Pharmacol Res. 2020; 160: 105052. doi:10.1016/j.phrs.2020.105052.; Chahoud J., Mrad J., Semaan A. Prevalence of diabetes mellitus among patients with essential arterial hypertension. J Med Liban. 2015;63(2):74-80. doi:10.12816/0012554.; Chernatska O., Demikhova N. Improvement of treatment in persons with arterial hypertension and type 2 diabetes mellitus. Georgian Med News. 2018; (284): 47-51.; Бабкин, А.П. Оптимизация лечения артериальной гипертензии у больных сахарным диабетом. Системный анализ и управление в биомедицинских системах. 2020; Т. 19, № 4:37-41. — DOI 10.36622/VSTU.2020.19.4.005.; Steffen P.L.S., Mendonça C.S., Meyer E. et al. Motivational Interviewing in the Management of Type 2 Diabetes Mellitus and Arterial Hypertension in Primary Health Care: An RCT. Am J Prev Med. 2021 May; 60(5): e203-e212. doi:10.1016/j.amepre.2020.12.015.; ElSayed N.A., Aleppo G., Aroda V.R. et al. Standards of Care in Diabetes—2023. Diabets Care. 2023; 46(S1): 1-291. doi: https://diabetesjournals.org/care/issue/46/Supplement_1Test; Comini L.O., de Oliveira L.C., Borges L.D. et al. Prevalence of chronic kidney disease in Brazilians with arterial hypertension and/or diabetes mellitus. J Clin Hypertens (Greenwich). 2020 Sep; 22(9): 1666-1673. doi:10.1111/jch.13980.; Gerstein H.C., Yusuf S., Mann J.F.E. et al. Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: Results of the HOPE study and MICRO-HOPE substudy. Heart Outcomes Prevention Evaluation Study Investigators. Lancet. 2000; 355: 253–259. https://www.thelancet.com/journals/lancet/article/PIIS0140-6736Test(99)12323-7/fulltext; Yusuf S., Teo K., Anderson C. et al. Telmisartan Randomised AssessmeNt Study in ACE iNtolerant subjects with cardiovascular Disease (TRANSCEND) Investigators; Effects of the angiotensin-receptor blocker telmisartan on cardiovascular events in high-risk patients intolerant to angiotensin-converting enzyme inhibitors: A randomised controlled trial. Lancet. 2008; 372: 1174–1183. https://www.sciencedirect.com/science/article/abs/pii/S0140673608612428Test; Williams B., Mancia G., Spiering W. 2018 ESC/ESH Guidelines for the management of arterial hypertension: The Task Force for the management of arterial hypertension of the European Society of Cardiology (ESC) and the European Society of Hypertension (ESH). European Heart Journal. 2018; 39(33): 3021–3104. https://doi.org/10.1093/eurheartj/ehy339Test; De Boer I.H., Bangalore S., Benetos А.et al. Diabetes and hypertension: a position statement by the American Diabetes Association. Diabetes care. 2017; 40 (9): 1273-1284. http://medi-guide.meditool.cn/ymtpdf/F042CABB-0E65-6FBB-5BED-D29701E8024A.pdfTest; Strawn W.B. Ferrario C.M. Mechanisms linking angiotensin II and atherogenesis. Curr. Opin. Lipidol. 2002; 13: 505–512. https://journals.lww.com/co-lipidology/abstract/2002/10000/mechanisms_linking_angiotensin_ii_and.6.aspxTest; de Boer I.H., Bangalore S., Benetos A. et all. Diabetes and Hypertension: A Position Statement by the American Diabetes Association. Diabetes Care. 2017; 40: 1273–1284. http://medi-guide.meditool.cn/ymtpdf/F042CABB-0E65-6FBB-5BED-D29701E8024A.pdfTest; Gerstein H.C., Mann J.F., Pogue J. et al. Prevalence and determinants of microalbuminuria in high-risk diabetic and nondiabetic patients in the Heart Outcomes Prevention Evaluation Study. The HOPE Study Investigators. Diabetes Care. 2000; 23 (Suppl. 2): 35–39. https://www.proquest.com/openview/766619903e52ede1e8b15966e32931c2/1?pq-origsite=gscholar&cbl=47715Test; Patel A. MacMahon S., Chalmers J. et al. Effects of a fixed combination of perindopril and indapamide on macrovascular and microvascular outcomes in patients with type 2 diabetes mellitus (the ADVANCE trial): A randomised controlled trial. Lancet. 2007; 370: 829–840. https://www.thelancet.com/journals/lancet/article/PIIS0140-6736Test(07)61303-8/fulltext?code=lancet-site&isEOP=true; Epstein M. Adding spironolactone to conventional antihypertensives reduces albuminuria in patients with diabetic nephropathy. Nat. Clin. Pract. Nephrol. 2006; 2: 310–311. https://www.nature.com/articles/ncpneph0192Test; Mehdi U.F., Adams-Huet B., Raskin P. et al. Addition of angiotensin receptor blockade or mineralocorticoid antagonism to maximal angiotensin-converting enzyme inhibition in diabetic nephropathy. J. Am. Soc. Nephrol. 2009; 20: 2641–2650. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2794224Test/; Xu G., Chen J., Jing G. et al. Preventing β-cell loss and diabetes with calcium channel blockers. Diabetes. 2012; 61: 848–856. https://diabetesjournals.org/diabetes/article/61/4/848/15920/Preventing-Cell-Loss-and-Diabetes-With-CalciumTest; Gupta A.K., Dahlof B., Dobson J. et al. Anglo-Scandinavian Cardiac Outcomes Trial Investigators. Determinants of new-onset diabetes among 19,257 hypertensive patients randomized in the Anglo-Scandinavian Cardiac Outcomes Trial--Blood Pressure Lowering Arm and the relative influence of antihypertensive medication. Diabetes Care. 2008; 31: 982–988. https://diabetesjournals.org/care/article/31/5/982/29987/Determinants-of-New-Onset-Diabetes-Among-19-257Test; Bangalore S., Parkar S., Grossman E. et al. A meta-analysis of 94,492 patients with hypertension treated with beta blockers to determine the risk of new-onset diabetes mellitus. Am. J. Cardiol. 2007; 100: 1254–1262. https://www.sciencedirect.com/science/article/abs/pii/S000291490701332XTest; Borges L.D., Comini L.O., de Oliveira L.C. et al. Hypertriglyceridemic waist phenotype and associated factors in individuals with arterial hypertension and/or diabetes mellitus. J Nutr Sci. 2021 Sep 14; 10: e74. doi:10.1017/jns.2021.71.; Nascimento-Souza M.A., Lima-Costa M.F., Peixoto S.V. “A body shape index” and its association with arterial hypertension and diabetes mellitus among Brazilian older adults: National Health Survey (2013). Cad Saude Publica. 2019; 35(8): e00175318. doi:10.1590/0102-311X00175318.; https://www.medarhive.ru/jour/article/view/1692Test

View record in BASE

7

دورية أكاديمية

Hypoglycemic Therapy and the Course of Post-Covid Syndrome, is There a Connection? ; Сахароснижающая терапия и течение постковидного синдрома, есть ли связь?

المؤلفون: G. A. Ignatenko, A. E. Bagriy, O. A. Prikolota, A. V. Prikolota, K. E. Mogilevskaya, Г. А. Игнатенко, А. Э. Багрий, О. А. Приколота, А. В. Приколота, К. Э. Могилевская

المصدر: The Russian Archives of Internal Medicine; Том 13, № 2 (2023); 129-135 ; Архивъ внутренней медицины; Том 13, № 2 (2023); 129-135 ; 2411-6564 ; 2226-6704

مصطلحات موضوعية: метформин, COVID-19 infection, post-COVID syndrome, dipeptidyl peptidase-4 inhibitors, metformin, инфекция COVID-19, постковидный синдром, ингибиторы дипептидилпептидазы-4

وصف الملف: application/pdf

العلاقة: https://www.medarhive.ru/jour/article/view/1595/1207Test; https://www.medarhive.ru/jour/article/view/1595/1215Test; Steenblock Ch., Schwarz P.E. H., Ludwig B. et al. COVID-19 and metabolic disease: mechanisms and clinical management. Lancet Diabetes Endocrinol. 2021; 9 (11): 786-798. https://doi.org/10.1016/S2213-8587Test(21)00244-8; Игнатенко Г.А., Багрий А.Э., Оприщенко А.А. и др. Сахарный диабет: руководство для врачей. Донецк, РБ Позитив. 2022; 640 с.; Apicella M., Campopiano M.C., Mazoni L. et al. COVID-19 in people with diabetes: understanding the reasons for worse out-comes. Lancet Diabetes Endocrinol. 2020; 8 (9): 782-792. doi:10.1016/S2213-8587(20)30238-2; Lim S., Bae J.H., Kwon H.S. et al. COVID-19 and diabetes mellitus: From pathophysiology to clinical management. Nat Rev Endocrinol. 2021; 17 (1): 11-30. https://doi.org/10.1038/s41574-020-00435-4Test; Davis H.E., Assaf G.S., McCorkell L. et al. Characterizing long COVID in an international: 7 months of symptoms and their impact. EClini-calMedicine. 2021; 38: 101019. https://doi.org/10.1016/j.eclinm.2021.101019Test; Nalbandian A., Sehgal K., Gupta A. et al. Post-acute COVID-19 syndrome. Nature Medicine. 2021; 27 (4): 601-615. doi:10.1038/s41591-021-01283-z; COVID-19 Treatment Guidelines Panel. Coronavirus Disease 2019 (COVID-19) Treatment Guidelines. National Institutes of Health. Available at https://www.covid19treatmentguidelines.nih.govTest/. Accessed [May 31, 2022]; Kosiborod M.N., Esterline R., Furtado R.H. M. et al. Dapagliflozin in patients with cardiometabolic risk factors hospitalised with COVID-19 (DARE-19): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Diabetes Endocrinol. 2021; 9 (9): 586-594. doi:10.1016/S2213-8587(21)00180-7; Manu P. Drug Therapy for Unexplained Dyspnea in Post-COVID-19 Fatigue Syndrome: Empagliflozin and Sildenafil. Am J Ther. 2022; 29 (4): e447-e448. doi:10.1097/MJT.0000000000001483. PMID: 35412483; Kang Y., Zhan F., He M. et al. Anti-inflammatory effects of sodium-glucose co-transporter 2 inhibitors on atherosclerosis. Vascul Pharmacol. 2020; 133-134: 106779. doi:10.1016/j.vph.2020.106779; Pawlos A., Broncel M., Wozniak E. et al. Neuroprotective effect of SGLT2 inhibitors. Molecules. 2021; 26: 7213. doi:10.3390/molecules26237213; Wiciński M., Wódkiewicz E., Górski K. et al. Perspective of SGLT2 inhibition in treatment of conditions connected to neuronal loss: focus on alzheimer’s disease and ischemia-related brain injury. Pharmaceuticals (Basel). 2020; 13: 379. doi:10.3390/ph13110379; Bornstein S.R., Rubino F., Khunti K. et al. Practical recommendations for the management of diabetes in patients with COVID-19. Lancet Diabetes Endocrinol. 2020; 8 (6): 546-550. doi:10.1016/S2213-8587(20)30152-2; Жмеренецкий К.В., Витько А.В., Петричко Т.А. и др. Сложные вопросы ведения пациентов с COVID-19, коморбидных по сердечно-сосудистым заболеваниям и сахарному диабету 2-го типа. Дальневосточный медицинский журнал. 2020; 2: 102-114.; Kleine-Weber H., Schroeder S., Krüger N. et al. Polymorphisms in dipeptidylpeptidase 4 reduce host cell entry of Middle East respiratory syndrome coronavirus. Emerg. Microbes Infect. 2020; 9 (1): 155-168. doi:10.1080/22221751.2020.1713705; Solerte S.B., D’Addio F., Trevisan R. et al. Sitagliptin treatment at the time of hospitalization was associated with reduced mortality in patients with type 2 diabetes and COVID-19: a multicenter case-control retrospective observational study. Diabetes Care. 2020; 43 (12): 2999-3006. https://doi.org/10.2337/dc20-1521Test; Mirani M., Favacchio G., Carrone F. et al. Impact of comorbidities, glycemia at admission, and DPP-4 inhibitors in type 2 diabetic patients with COVID-19: a case series from an academic hospital in Lombardy, Italy. Diabetes Care. 2020; 43 (12): 3042-3049. https://doi.org/10.2337/dc20-1340Test; Dalan R., Ang L.W., Tan W.Y. T. et al. The association of hypertension and diabetes pharmacotherapy with COVID-19 severity and immune signatures: an observational study. Eur. Heart J. Cardiovasc. Pharmacother. 2021; 7 (3): e48-e51. https://doi.org/10.1093/ehjcvp/pvaa098Test; Scherer P.E., Kirwan J.P., Rosen C.J. Post-acute sequelae of COVID-19: A metabolic perspective. Elife. 2022; 11: e78200. doi:10.7554/eLife.78200; https://www.medarhive.ru/jour/article/view/1595Test

الإتاحة: https://doi.org/10.20514/2226-6704-2023-13-2-129-135Test
https://doi.org/10.1016/S2213-8587Test(21)00244-8
https://doi.org/10.1016/S2213-8587Test(20)30238-2
https://doi.org/10.1038/s41574-020-00435-4Test
https://doi.org/10.1016/j.eclinm.2021.101019Test
https://doi.org/10.1038/s41591-021-01283-zTest
https://doi.org/10.1016/S2213-8587Test(21)00180-7
https://doi.org/10.1097/MJT.0000000000001483Test
https://doi.org/10.1016/j.vph.2020.106779Test
https://doi.org/10.3390/molecules26237213Test

View record in BASE

8

دورية أكاديمية

Treatment of Patients Chronic Coronary Heart Disease and Type 2 Diabetes Mellitus ; Лечение пациентов с хронической ишемической болезнью сердца и сахарным диабетом 2 типа

المؤلفون: E. V. Shсhukina, O. A. Prikolota, V. A. Bagrij, A. Yu. Andrusjak, G. S. Rybalko, Yu. B. Shesterina, E. A. Stefano, Е. В. Щукина, О. А. Приколота, В. А. Багрий, А. Ю. Андрусяк, Г. С. Рыбалко, Ю. Б. Шестерина, Е. А. Стефано

المصدر: The Russian Archives of Internal Medicine; Том 13, № 2 (2023); 97-109 ; Архивъ внутренней медицины; Том 13, № 2 (2023); 97-109 ; 2411-6564 ; 2226-6704

مصطلحات موضوعية: сердечно-сосудистый прогноз, type 2 diabetes mellitus, cardiovascular diseases, cardiovascular prognosis, сахарный диабет 2 типа, сердечно-сосудистые заболевания

وصف الملف: application/pdf

العلاقة: https://www.medarhive.ru/jour/article/view/1592/1204Test; https://www.medarhive.ru/jour/article/view/1592/1212Test; Ferrannini G, De Bacquer D, De Backer G, et al. EUROASPIRE V collaborators. Screening for glucose perturbations and risk factor management in dysglycemic patients with coronary artery disease — a persistent challenge in need of substantial improvement: a report from ESC EORP EUROASPIRE V. Diabetes Care. 2020;43(4): 726–733. doi:10.2337/dc19-2165.; Ferranini G., Norhammar A., Gyberg V. et al. Is coronary artery disease inevitable in type 2 diabetes? From a glucocentric to a holistic view on patient management. Diabetes Care. 2020; 43 (9): 2001-2009. doi:10.2337/dci20-0002.; Arnett DK, Blumenthal RS, Albert MA et al. 2019 ACC/AHA guideline on the primary prevention of cardiovascular disease: a report of the American College of Cardiology. American Heart Association Task Force on Clinical Practice Guidelines. Circulation. 2019; 140: 596–646. doi:10.1161/CIR.0000000000000678; Evert AB, Dennison M, Gardner CD et al. Nutrition Therapy for Adults With Diabetes or Prediabetes: A Consensus Report. Diabetes Care. 2019; 42(5): 731-754. doi:10.2337/dci19-0014; Boer de L., Caramori M., Chan J. et al. Executive summary of the 2020 KDIGO Diabetes management in CKD Guideline: Evidence-based advances in monitoring and treatment. Kidney Int.2020; 98: 839–848. doi:10.1016/j.kint.2020.06.024; Arnold SV, Bhatt DL, Barsness GW, et al. Clinical management of stable coronary artery disease in patients with type 2 diabetes mellitus: a scientific statement from the American Heart Association. Circulation. 2020; 141: 779–806. doi:10.1161/CIR.0000000000000766; Colberg SR, Sigal RJ, Yardley JE, et al. Physical activity/exercise and diabetes: a position statement of the American Diabetes Association. Diabetes Care. 2016; 39: 2065–2079. doi:10.2337/dc16-1728; Newman J.D., Schwartzbard A.Z., Weintraub H.S., et al. Primary prevention of cardiovascular disease in diabetes mellitus. JACC. 2017; 70(7): 883-893. doi:10.1016/j.jacc.2017.07.001; Cosentino F. GPJ, Aboyans V., Bailey C.J. et al. 2019 ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD: The Task Force for diabetes, pre-diabetes, and cardiovascular diseases of the European Society of Cardiology (ESC) and the European Association for the Study of Diabetes (EASD). European Heart Journal. 2020; 41(2): 255-323. doi:10.1093/eurheartj/ehz486.; Bates E.R. Antiplatelet therapy in patients with coronary disease and type 2 diabetes. N Engl J Med. 2019; 381(14): 1373-1375. doi:10.1056/NEJMe1910813; Joshua J. Joseph, Prakash Deedwania, Tushar Acharya, et al. Comprehensive Management of Cardiovascular Risk Factors for Adults With Type 2 Diabetes: A Scientific Statement From the American Heart Association. Circulation. 2022; 145: 722–759. doi:10.1161/CIR.0000000000001040.; Connolly SJ, Eikelboom JW, Bosch J, et al; COMPASS Investigators. Rivaroxaban with or without aspirin in patients with stable coronary artery disease: an international, randomised, double-blind, placebo-controlled trial. Lancet. 2018; 391: 205–218. doi:10.1016/S0140-6736(17)32458-3; American Diabetes Association. 10. Cardiovascular disease and risk management: Standards of Medical Care in Diabetes. 2020. Diabetes Care. 2020; 43(1): 111–134. doi.org/10.2337/dc20-s010; Deedwania P. The ongoing saga of optimal blood pressure level in patients with diabetes mellitus and coronary artery disease. J Am Heart Assoc. 2018; 7: e010752. doi:10.1161/JAHA.118.010752; Ettehad D, Emdin CA, Kiran A, et al. Blood pressure lowering for prevention of cardiovascular disease and death: a systematic review and meta-analysis. Lancet. 2016; 387: 957–967. doi:10.1016/S0140-6736(15)01225-8; Goldberg R.B., Stone N.J., Grundy S.M. The 2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guidelines on the Management of Blood Cholesterol in Diabetes. Diabetes Care 2020; 43(8): 1673-1678. doi 10.2337/dci19-0036; Berberich A., Hegele R.A. LDL cholesterol: lower, faster, younger? Lancet Diabetes Endocrinology. 2020; 8(1): 5-7. doi:10.1016/S2213-8587(19)30389-4.; François M, Colin B, Alberico LC, et. al. 2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk: The Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and European Atherosclerosis Society (EAS). European Heart Journal. 2020; 41 (1): 111–188. doi.org/10.1093/eurheartj/ehz455; Grundy SM, Stone NJ, Bailey AL, et al., 2018 AHA/ACC/AACVPR/ AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Blood Cholesterol. Journal of the American College of Cardiology. Circulation. 2019; 73 (24): 285–350. doi:10.1016/j.jacc.2018.11.003.; Erqou S, Lee CC, Adler AI. Statins and glycaemic control in individuals with diabetes: a systematic review and meta-analysis. Diabetologia. 2014; 57: 2444–2452. doi:10.1007/s00125-014-3374-x; Newman C.B., Preiss D., Tobert J.A. et al. Statin safety and associated adverse events: A scientific statement from the American Heart Association.Arteriosclerosis, Thrombosis and Vascular Biology. 2019; 39(2): 38-81. doi:10.1161/ATV.0000000000000073.; Смолина М.О., Бенимецкая К.С., Рагино Ю.И. и др. PCSK9: новые победы и горизонты. Атеросклероз. 2018; 14(3): 70-77. doi:10.15372/ATER20180311.; Landmesser U, Chapman MJ, Stock JK et al. 2017 Update of ESC/ EAS Task Force on Practical Clinical Guidance for proprotein convertase subtilisin/kexin type 9 inhibition in patients with atherosclerotic cardiovascular disease or in familial hypercholesterolaemia. Eur Heart J. 2018; 39: 1131–1143. doi:10.1093/eurheartj/ehx549; Bowman L., Mafham M., Wallendszus K. et al. Effects of n-3 fatty acid supplements in diabetes mellitus . N Engl J Med. 2018; 379: 1540-50. doi:10.1056/NEJMoa1804989; Bhatt DL, Steg PG, Miller M et al; REDUCE-IT Investigators. Cardiovascular risk reduction with icosapentethyl for hypertriglyceridemia. N Engl J Med. 2019; 380: 11–22. doi:10.1056/NEJMoa1812792; Abhinav Sharma, Neha J. Pagidipati, et al. Impact of Regulatory Guidance on Evaluating Cardiovascular Risk of New Glucose-Lowering Therapies to Treat Type 2 Diabetes Mellitus Lessons Learned and Future Directions. Circulation. 2020; 141: 843–862. doi:10.1161/CIRCULATIONAHA.119.041022; American Diabetes Association. 6. Glycemic targets: Standards of Medical Care in Diabetes 2020. Diabetes Care. 2020; 43(1): 66–76. doi:10.2337/dc20-S006.; Lee AK, Warren B, Lee CJ, et al. The association of severe hypoglycemia with incident cardiovascular events and mortality in adults with type 2 diabetes. Diabetes Care. 2018; 41: 104–111. doi:10.2337/dc17-1669; Ворожцова И.Н., Будникова О.В., Афанасьев С.А. и др. Влияние сахарного диабета 2-го типа на миокард пациентов с ишемической болезнью сердца. Сибирский медицинский журнал. 2018; 33(1): 14-20. doi:10.29001/2073-8552-2018-33-1-14-20; Багрий А.Э., Супрун Е.В., Михайличенко Е.С. и др. Хроническая сердечная недостаточность и сахарный диабет 2 типа: состояние проблемы. Российский кардиологический журнал. 2020; 25(4): 3858. doi:10.15829/1560-4071-2020-3858.; Дедов И.И., Шестакова М.В., Майоров А.Ю. и др. Сахарный диабет 2 типа у взрослых. Клинические Рекомендации. Сахарный диабет. 2020; 23(2): 4-102. doi:10.14341/DM12507.; Liu D, Jin B, Chen W, et al. Dipeptidyl peptidase 4 (DPP-4) inhibitors and cardiovascular outcomes in patients with type 2 diabetes mellitus (T2DM): a systematic review and meta-analysis. BMC Pharmacol Toxicol. 2019; 20: 15. doi:10.1186/s40360-019-0293-y; Шумилова Н.А., Павлова С.И. Глифлозины: гликемические и негликемические эффекты. Acta medica Eurasia. 2019; 1: 44-51. doi: acta-medica-eurasica.ru/single/2019/1/6/.; Heerspink H.J. L., Stefansson B.V., Chertow G.M. et al. Rationale and protocol of the Dapagliflozin And Prevention of Adverse outcomes in Chronic Kidney Disease (DAPA-CKD) randomized controlled trial. Nephrol Dial Transplant. 2020; 35: 274–282. doi:10.1093/ndt/gfz290.; Lo K.B., Gul F., Ram P. et al. The Effects of SGLT2 Inhibitors on Cardiovascular and Renal Outcomes in Diabetic Patients: A Systematic Review and Meta-Analysis. Cardiorenal Med. 2020; 10: 1–10. doi:10.1159/000503919.; Perkovic V., Jardine M.J., Neal B. et al. Canagliflozin and renal outcomes in type 2 diabetes and nephropathy. N Engl J Med. 2019; 380: 2295-2306. doi:10.1056/NEJMoa1811744.; Kristensen SL, Rorth R, Jhund PS, et al. Cardiovascular, mortality, and kidney outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials. Lancet Diabetes Endocrinol .2019; 7: 776-785. doi:10.1016/S2213-8587(19)30249-9.; Ghosh-Swaby O.R., Goodman S.G., Leiter L.A. et al. Glucose-lowering drugs or strategies, atherosclerotic cardiovascular events, and heart failure in people with or at risk of type 2 diabetes: an updated systematic review and meta-analysis of randomized cardiovascular outcome trials. Lancet Diabetes and Endocrinology. 2020; 8(5): 418-435. doi:10.1016/S2213-8587(20)30038-3; Marso SP, Daniels GH, Brown-Frandsen K et al; LEADER Steering Committee; LEADER Trial Investigators. Liraglutide and cardiovascular outcomes in type 2 diabetes. N Engl J Med. 2016; 375: 311–322. doi:10.1056/NEJMoa1603827; Bonora B.M., Avogaro A., Fadini G.P. Extraglycemic effects of SGLT2 Inhibitors: A review of the evidence. Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy. 2020; 13: 161–174. doi:10.2147/DMSO.S233538; Buse JB, Wexler DJ, Tsapas A, et al. 2019 Update to: management of hyperglycemia in type 2 diabetes, 2018: a consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care. 2020; 43: 487–493. doi:10.2337/dci19-0066; Knuuti J., Wijns W., Saraste A. et al. 2019 ESC Guidelines for the diagnosis and management of chronic coronary syndromes. Eur. Heart J. 2020; 41: 407-477. doi:10.1093/eurheartj/ehz425.; Mancini GBJ, Boden WE, Brooks MM et al. Impact of treatment strategies on outcomes in patients with stable coronary artery disease and type 2 diabetes mellitus according to presenting angina severity: a pooled analysis of three federally-funded randomized trials. Atherosclerosis. 2018; 277: 186–194. doi:10.1016/j.atherosclerosis.2018.04.005; Kosiborod M, Arnold SV, Spertus JA et al. Evaluation of ranolazine in patients with type 2 diabetes mellitus and chronic stable angina: results from the TERISA randomized clinical trial (Type 2 Diabetes Evaluation of Ranolazine in Subjects With Chronic Stable Angina). J Am Coll Cardiol. 2013; 61: 2038–2045. doi:10.1016/j.jacc.2013.02.011; Farkouh ME, Domanski M, Dangas GD et al; FREEDOM Follow-On Study Investigators. Long-term survival following multivessel revascularization in patients with diabetes: the FREEDOM Follow-On Study. J Am Coll Cardiol. 2019; 73: 629–638. doi:10.1016/j.jacc.2018.11.001; Bhatt DL. CABG the clear choice for patients with diabetes and multivessel disease. Lancet. 2018; 391: 913–914. doi:10.1016/S0140-6736(18)30424-0; Neumann FJ, Sousa-Uva M, Ahlsson A et al; ESC Scientific Document Group. 2018 ESC/EACTS guidelines on myocardial revascularization. Eur Heart J. 2019; 40: 87–165. doi:10.1093/eurheartj/ehy394; Doenst T, Haverich A, Serruys P, et al. PCI and CABG for treating stable coronary artery disease: JACC review topic of the week. J Am Coll Cardiol. 2019; 73: 964–976. doi:10.1016/j.jacc.2018.11.053; Head SJ, Milojevic M, Daemen J. et al. Mortality after coronary artery bypass grafting versus percutaneous coronary intervention with stenting for coronary artery disease: a pooled analysis of individual patient data. Lancet. 2018; 391: 939–948. doi:10.1016/S0140-6736(18)30423-9; https://www.medarhive.ru/jour/article/view/1592Test

الإتاحة: https://doi.org/10.20514/2226-6704-2023-13-2-97-109Test
https://doi.org/10.2337/dc19-2165Test
https://doi.org/10.1161/CIR.0000000000000678Test
https://doi.org/10.2337/dci19-0014Test
https://doi.org/10.1016/j.kint.2020.06.024Test
https://doi.org/10.1161/CIR.0000000000000766Test
https://doi.org/10.2337/dc16-1728Test
https://doi.org/10.1016/j.jacc.2017.07.001Test
https://doi.org/10.1093/eurheartj/ehz486Test
https://doi.org/10.1056/NEJMe1910813Test

View record in BASE

تنقيح النتائج